Bullish & Foolish
Full CODX fundamentals All 466 on the Survival Watch

CODXCO-DIAGNOSTICS, INC.

Is Co-Diagnostics struggling financially?

Yes, by its own account. Co-Diagnostics told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$7.6M
Source filing
10-Q 14 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 1month

    If the burn speeds up

    Empty by Jul 2026

  • 2months

    If it eases off

    Empty by Aug 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$3.6M

÷

Cash burned over the last 12 months

$29.8M

What Co-Diagnostics told the SEC

…If we are not able to obtain additional debt or equity financing on a timely basis, the impact on us will be material and adverse. These uncertainties create substantial doubt about our ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties .

CO-DIAGNOSTICS, INC., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Cash burn is narrowing It is spending 47% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt